Host-Directed Drug Targeting of Factors Hijacked by Pathogens
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
The current paradigm for managing infectious diseases has targeted unique processes or enzymes within pathogens. A serious disadvantage of this pathogen-directed drug targeting strategy has been the development of microbial drug resistance and consequent resurgence of once-contained infectious diseases. A new drug discovery paradigm has therefore emerged focusing on identifying and targeting host factors essential for pathogen entry, survival, and replication. Innovative strategies combining genome-wide computational biology, genomics, proteomics, and traditional forward and reverse genetics have identified host-pathogen interactions and host functions critical for the establishment of infection. Chemogenomics and chemical genetics have allowed rapid identification of new and existing licensed drugs with antimicrobial activity. Although most host-directed drug targeting studies have focused on viral infections, they have provided a proof of concept for similar approaches to bacterial and parasite infections. Future therapies may combine conventional targeting of microbial virulence factors, together with host-directed drug therapy and augmentation of protective host factors, to efficiently eliminate the invading pathogen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2008) · doi:10.1038/nrg2290 · Cited by 5,199
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605298103 · Cited by 4,317
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R., MacDonald, M. E., Stuhlmann, H., Koup, R. A., & Landau, N. R. (1996) · Cell · doi:10.1016/s0092-8674(00)80110-5 · Cited by 3,074
MicroRNA-155 is induced during the macrophage inflammatory response
O'Connell, R. M., Taganov, K. D., Boldin, M. P., Cheng, G., & Baltimore, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0610731104 · Cited by 1,866
Robertson, G., Hirst, M., Bainbridge, M., Bilenky, M., Zhao, Y., Zeng, T., Euskirchen, G., Bernier, B., Varhol, R., Delaney, A., et al. (2007) · Nature Methods · doi:10.1038/nmeth1068 · Cited by 1,454 · cited 1×
“The DNA sequences are purified and identified by hybridization to whole-genome DNA microarrays (ChIP-chip) (106) or by direct DNA sequencing (ChIP-Seq) (107).”
Identification of host proteins required for HIV infection through a functional genomic screen
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., & Elledge, S. J. (2008) · Science · doi:10.1126/science.1152725 · Cited by 1,449
The biology and future prospects of antivirulence therapies
Cegelski, L., Marshall, G. R., Eldridge, G. R., & Hultgren, S. J. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1818 · Cited by 788
O'Connell, R. M., Rao, D. S., Chaudhuri, A. A., Boldin, M. P., Taganov, K. D., Nicoll, J., Paquette, R. L., & Baltimore, D. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072108 · Cited by 681
MicroRNAs and immunity: Novel players in the regulation of normal immune function and inflammation
Sonkoly, E., Ståhle, M., & Pivarcsi, A. (2008) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2008.01.005 · Cited by 523
Cited by
Metformin as adjunct antituberculosis therapy
Singhal, A., Jie, L., Kumar, P., Hong, G. S., Leow, M. K.-S., Paleja, B., Tsenova, L., Kurepina, N., Chen, J., Zolezzi, F., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009885 · Cited by 547
“These “host-targeted” adjunct therapeutic strategies are less likely to engender microbial resistance than direct targeting of the pathogen with conventional drugs (6).”
BackgroundLabel-free biological and chemical sensors
Hunt, H. K., & Armani, A. M. (2010) · Nanoscale · doi:10.1039/c0nr00201a · Cited by 371
Ten years of dengue drug discovery: Progress and prospects
Lim, S. P., Wang, Q.-Y., Noble, C. G., Chen, Y.-L., Dong, H., Zou, B., Yokokawa, F., Nilar, S., Smith, P., Beer, D., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.013 · Cited by 350
Parihar, S. P., Guler, R., Khutlang, R., Lang, D. M., Hurdayal, R., Mhlanga, M. M., Suzuki, H., Marais, A. D., & Brombacher, F. (2014) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit550 · Cited by 312
Self-citationStanley, S. A., Barczak, A. K., Silvis, M. R., Luo, S. S., Sogi, K., Vokes, M., Bray, M.-A., Carpenter, A. E., Moore, C. B., Siddiqi, N., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1003946 · Cited by 251
“In contrast to work studying therapies that potentially manipulate immunity at a systemic level, a growing body of literature including this current work supports the idea that targeting specific host-pathways to enhance molecular mechanisms for bacterial clearance on the cellular level may be an effective adjunctive…”
ResultDe Muylder, G., Ang, K. K. H., Chen, S., Arkin, M. R., Engel, J. C., & McKerrow, J. H. (2011) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0001253 · Cited by 232
“It is assumed to be less likely to induce drug resistant pathogens and offers the possibility to repurpose drugs by exploiting compounds currently used for diseases unrelated to microbial infection [38,39].”
BackgroundMutation rate and the emergence of drug resistance in Mycobacterium tuberculosis
McGrath, M., Gey van Pittius, N. C., van Helden, P. D., Warren, R. M., & Warner, D. F. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt364 · Cited by 161
New role for FDA-approved drugs in combating antibiotic-resistant bacteria
Andersson, J. A., Fitts, E. C., Kirtley, M. L., Ponnusamy, D., Peniche, A. G., Dann, S. M., Motin, V. L., Chauhan, S., Rosenzweig, J. A., Sha, J., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00326-16 · Cited by 53
Metadata
- Authors
- Schwegmann, A., & Brombacher, F.
- Venue
- Science Signaling
- Published
- 2008-07-22
- Volume
- 1
- Issue
- 29
- Pages
- re8-re8
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2150893994
- Cited by
- 127
- References
- 16
- FWCI
- 9.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.